Related Experiment Videos
Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses
S I Abrams1, S F Stanziale, S D Lunin
1Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, MD 20892-1750, USA.
Abstract:
Mutant ras p21 proteins contain sequences which distinguish them from normal endogenous ras and, thus, may represent unique epitopes for T cell recognition of antigen bearing tumor cells. Here, we examined the capacity of a mutant K-ras 9-mer peptide to induce in vivo CD8+ cytotoxic T lymphocytes (CTL). The peptide chosen reflected positions 4-12 of the point-mutated sequence of the K-ras oncogene encoding the Gly to Val substitution at codon 12. The overall rationale for selecting this particular 9-mer sequence was threefold: the mutant peptide contained a putative major histocompatibility complex (MHC) class I consensus anchor motif for murine H-2Kd; specific binding to MHC class I may then create an immunogenic complex for the induction of anti-ras CD8+ CTL; and finally, the mutant sequence overlapped with a newly characterized anti-ras CD4+ T helper type 1 epitope, which may have implications for the coordination and activation of both anti-ras immune mechanisms against the same target cell antigenic determinant. A functional interaction with H-2Kd was demonstrated with the mutant ras4-12(V12) peptide, but not the normal ras4-12(G12) peptide, which specifically inhibited an H-2Kd-restricted, anti-nucleoprotein NP147-155 CTL response in a dose-dependent fashion. An anti-ras CD8+ T cell line was then established from immune splenocytes of BALB/c (H-2d) mice injected with ras4-12 (V12) in adjuvant, which mediated peptide-specific lysis of syngeneic P815 tumor targets. Cytotoxicity was restricted by H-2Kd and strongly specific for the mutant ras peptide. Importantly, these anti-ras CTL specifically lysed a syngeneic tumor line (i.e. A20 lymphoma) transduced with the corresponding point-mutated ras oncogene, suggesting T cell receptor recognition of endogenously derived antigen. Overall, these data demonstrated that mutant ras p21 at codon 12(Gly-->Val) contained a peptide sequence which exhibited specific functional binding to a murine MHC class I molecule; the ability of the mutant, but not the normal sequence to bind selectively to murine MHC class I likely reflected the generation of a C-terminal anchor residue; and the ras4-12(V12) peptide was immunogenic for the production of antigen-specific CD8+ CTL, which lysed in vitro a syngeneic tumor cell line harboring the mutant K-ras oncogene.
Insights
Mutant ras peptides can trigger CD8+ cytotoxic T lymphocytes (CTL) to target tumor cells. This study shows a specific mutant K-ras peptide induces anti-ras CTL, demonstrating potential for cancer immunotherapy.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Mutant ras p21 proteins possess unique sequences distinct from normal ras, offering potential T cell recognition epitopes.
- Tumor cells expressing mutant ras oncoproteins are targets for immune surveillance.
Purpose of the Study:
- To investigate the capacity of a mutant K-ras 9-mer peptide to induce CD8+ cytotoxic T lymphocytes (CTL) in vivo.
- To assess the immunogenicity and specificity of a mutant ras peptide for anti-tumor immune responses.
Main Methods:
- A mutant K-ras 9-mer peptide (positions 4-12, Gly to Val substitution at codon 12) was designed based on MHC class I binding motifs.
- Functional binding to H-2Kd was assessed using a peptide inhibition assay.
- An anti-ras CD8+ T cell line was generated from immunized mice and tested for peptide-specific cytotoxicity against tumor targets.
Main Results:
- The mutant ras4-12(V12) peptide demonstrated functional binding to H-2Kd, unlike the normal ras4-12(G12) peptide.
- An H-2Kd-restricted, peptide-specific CD8+ T cell line was established, mediating lysis of syngeneic tumor cells.
- These CTL specifically recognized and lysed a syngeneic tumor line engineered to express the mutant K-ras oncogene.
Conclusions:
- Mutant ras p21 at codon 12 contains a peptide sequence capable of specific binding to murine MHC class I molecules.
- The mutant ras peptide is immunogenic, inducing antigen-specific CD8+ CTL.
- These CTL can effectively lyse tumor cells expressing the endogenous mutant K-ras oncogene, highlighting a potential therapeutic strategy.